Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 329.19M P/E - EPS this Y -7.90% Ern Qtrly Grth -
Income -184.35M Forward P/E -55.93 EPS next Y 73.20% 50D Avg Chg -15.00%
Sales 303.91M PEG -1.22 EPS past 5Y -42.23% 200D Avg Chg -28.00%
Dividend N/A Price/Book 0.88 EPS next 5Y 15.00% 52W High Chg -66.00%
Recommedations 1.70 Quick Ratio 1.38 Shares Outstanding 40.63M 52W Low Chg 3.00%
Insider Own 5.42% ROA -5.82% Shares Float 39.02M Beta 0.65
Inst Own 81.82% ROE -63.15% Shares Shorted/Prior 1.25M/1.39M Price 8.39
Gross Margin 50.90% Profit Margin -60.66% Avg. Volume 370,435 Target Price 13.33
Oper. Margin -12.21% Earnings Date Oct 3 Volume 252,090 Change -2.44%
About AngioDynamics, Inc.

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.

AngioDynamics, Inc. News
11/19/24 NVRO Stock Declines Despite Positive Study Data of Nevro1 System
11/18/24 INBS Stock Declines Despite Positive Results of Pharmacokinetic Study
11/05/24 Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
11/01/24 Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's is How to Trade
10/30/24 GE HealthCare Q3 Earnings Beat Estimates, Sales Meet, Net Margin Up
10/29/24 Investors in AngioDynamics (NASDAQ:ANGO) have unfortunately lost 77% over the last three years
10/29/24 AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?
10/24/24 AngioDynamics launches long-term study of NanoKnife for prostate cancer
10/23/24 ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
10/23/24 AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System
10/22/24 AngioDynamics’ NanoKnife System gains CPT codes for prostate and liver treatments
07:00 AM AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver
10/08/24 AngioDynamics (ANGO) Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10/04/24 AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise
10/04/24 AngioDynamics Sees Growth Amidst Challenges in Fiscal 2025
10/04/24 Q1 2025 AngioDynamics Inc Earnings Call
10/04/24 AngioDynamics Inc (ANGO) Q1 2025 Earnings Call Transcript Highlights: A Promising Start with ...
10/03/24 Why AngioDynamics Stock Is Crashing Today
10/03/24 Here's Why You Should Add AngioDynamics Stock to Your Portfolio
10/03/24 AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates
ANGO Chatroom

User Image justforfun1234 Posted - 2 weeks ago

$ANGO business must be good if there holding on to the factory in NY! Demand must be booming!

User Image justforfun1234 Posted - 2 weeks ago

$ANGO BREAKING: Angiodynamics to stay in Queensbury October 29, 2024 AngioDynamics will keep 40% of its current workforce and continue on in Queensbury instead of closing entirely, Town Supervisor John Strough told The Chronicle. In January, The Chronicle reported that the AngioDynamics closure would cost 350 jobs in Glens Falls and Queensbury in 2025. Mr. Strough said Saleem Cheeks, VP Communications for AngioDynamics, said that “40% of their current workforce will be kept to ensure their new business plan; that being, keeping some of their mid-tech cardio vascular and oncology device manufacturing and growing their distribution out of their Queensbury facility.” Mr. Strough continued, “I was assured that most of the other 60% will pursue retirement or be deployed within the company elsewhere. “Because this is part of their new business plan, I was assured that this would be sustainable. “If help was needed, I assured Mr. Cheeks, the Town Board will work with and help AngioDynamics.”

User Image chuckthebarber Posted - 2 weeks ago

$ANGO

User Image justforfun1234 Posted - 10/30/24

$ANGO once prostate cancer is approved with reimbursement we are off to the races. 1 in 8 American men will be diagnosed with prostate cancer and this is an amazing treatment. Quick, low side effects and cost effective. If we capture 50-60k in America at 7000 a piece we are looking at 350-420 million annual sales! Buy now don’t be surprised if this hits 20-30. Let’s go!

User Image rcarigl23 Posted - 10/29/24

$NSPR so many possible buyers for this: $MDT, $BSX, $ANGO, $JNJ … a lot of them!!! And this is quite as hell; nobody says anything….. 🤔

User Image justforfun1234 Posted - 10/29/24

$ANGO needs to hold 7!

User Image Snihhga Posted - 10/25/24

$ANGO should become interesting soon. Watch

User Image BillyBobBleach Posted - 10/24/24

$ANGO pos stock. Almost seems too obvious that this should be $14-16 range. They’re keeping it low

User Image EarningsCentral Posted - 10/23/24

$ANGO Earnings Call Recap for Q1 2025 https://youtu.be/WJ9yHCpbAGY

User Image Thestocktraderhubzee Posted - 10/23/24

$ANGO AngioDynamics, University College London Hospital Launch International Multi-Center Study On Long Term Effects Of Treatment With NanoKnife System

User Image abc3000 Posted - 10/22/24

$ANGO Buy it!

User Image Stocksrunner Posted - 10/22/24

🎉 $AMLI $ANGO $LAC $ACB $SGML all started the day down but powered through to close up!

User Image justforfun1234 Posted - 10/22/24

$ANGO maybe a buyout incoming? Someone maybe trying to buy this out on the cheap!

User Image justforfun1234 Posted - 10/22/24

$ANGO under 10 is a gift!

User Image StockBoyAri Posted - 10/22/24

$ANGO moving

User Image justforfun1234 Posted - 10/22/24

$ANGO told you…

User Image justforfun1234 Posted - 1 month ago

$ANGO we are moving to 7 let’s go!

User Image justforfun1234 Posted - 1 month ago

$ANGO nice nanoknife codes for liver and prostate! This should make reimbursement easy for doctors!

User Image justforfun1234 Posted - 1 month ago

$ANGO once they get the clearance for prostate cancer I think we jet!

User Image BillyBobBleach Posted - 1 month ago

$ANGO pos is overdue to take off

User Image insiderbuyingselling Posted - 1 month ago

$ANGO new insider buying: 868 shares. http://insiderbuyingselling.com/?t=ANGO

User Image TheLearnerEarner Posted - 1 month ago

$ANGO ✅ UNDERVALUED stock swing trade - healthcare - small cap - 5/9 F-Score - 0.66x relative volume - 1x analyst outperform rating - 2x analysts buy rating - analysts in good agreement that stock price may potentially rise by 113.8% - short to medium term gains 📈 RSI: 30.29 (oversold bullish) 📊🐂 Analyst Price Target: $13.00 - $14.70 (113.82% - 142.98% above Price) 🌟 Range (12m) $5.26 - $8.25 💰 NEWSDESK (article idea is for ANGO only) 📰 https://finance.yahoo.com/news/angiodynamics-ango-loses-15-86-133506875.html

User Image TalkMarkets Posted - 1 month ago

3 Stocks Insiders Are Buying Heavily In October 2024, And Why $ANGO $ETON $TTSH https://talkmarkets.com/content/stocks--equities/3-stocks-insiders-are-buying-heavily-in-october-2024-and-why?post=464702

User Image LockPopSell Posted - 1 month ago

$ANGO backing up my truck, boat, and trailer at this level

User Image chrisx_1 Posted - 1 month ago

$ANGO It is time to buy ANGO. Zacks ranked strong buy.

User Image insiderbuyingselling Posted - 1 month ago

$ANGO new insider buying: 20000 shares. http://insiderbuyingselling.com/?t=ANGO

User Image insiderbuyingselling Posted - 1 month ago

$ANGO new insider buying: 1700 shares. http://insiderbuyingselling.com/?t=ANGO

User Image justforfun1234 Posted - 1 month ago

$ANGO I guess Jim bought 20k shares in open market. Good to see him step up a bit.

User Image justforfun1234 Posted - 1 month ago

$ANGO based on current valuation Auryon itself is worth more than the current enterprise value. The management should start looking at selling the company as their transformation is really taking long and their communication with investors has been awful. They need to do a better job at promoting stuff. I follow this company closely and didn’t know they filed with fda for nanoknife prostate cancer approval. Nor that the results were positive. Terrible PR.

User Image tradingtwenty Posted - 1 month ago

Top 5 oversold stocks that have trended in the past 24 hours: $ACHC 16.14🔥 $WEST 24.79 $AMN 25.79 $ARI 26.12 $ANGO 26.16 Values range from 0 to 100, where 30 or below is oversold and 70 or above overbought. Link: https://tradingtwenty.com/dashboard/trending/past

Analyst Ratings
HC Wainwright & Co. Buy Sep 20, 24
Canaccord Genuity Buy Jul 17, 24
HC Wainwright & Co. Buy Jul 17, 24
HC Wainwright & Co. Buy May 22, 24
Oppenheimer Outperform Apr 5, 24
Raymond James Outperform Jan 9, 24
HC Wainwright & Co. Buy Jan 8, 24
Raymond James Outperform Oct 6, 23
Canaccord Genuity Buy Oct 5, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Helsel Dave SVP Global Operation.. SVP Global Operations and R&D Apr 28 Sell 22.44 3,513 78,832 22,874 05/02/22
DONNELLY HOWARD W Director Director Apr 20 Option 15.95 6,022 96,051 104,734 04/21/22
JOHNSON WESLEY Director Director Apr 11 Sell 23.13 7,500 173,475 79,704 04/13/22
Trowbridge Stephen A EVP and CFO EVP and CFO Jan 12 Buy 22.64 1,000 22,640 76,081 01/12/22
Clemmer James C President and CEO President and CEO Jan 11 Buy 22.84 10,000 228,400 390,764 01/12/22
Centea Scott Sr. VP/GM, Global VI.. Sr. VP/GM, Global VIT Oct 15 Option 16.77 12,000 201,240 58,244 10/18/21
Centea Scott Sr. VP/GM, Global VI.. Sr. VP/GM, Global VIT Oct 15 Sell 27.92 12,000 335,040 46,244 10/18/21
Meteny Dennis S Director Director Jul 30 Option 14.64 5,726 83,829 117,865 07/30/21
Trowbridge Stephen A EVP and CFO EVP and CFO Apr 16 Option 14.07 13,625 191,704 73,371 04/16/21
DONNELLY HOWARD W Director Director Apr 05 Option 14.64 5,726 83,829 96,595 04/05/21